Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
How can we best monitor 5-FU administration to maximize benefit to risk ratio?
Goirand F, Lemaitre F, Launay M, Tron C, Chatelut E, Boyer JC, Bardou M, Schmitt A. Goirand F, et al. Among authors: bardou m. Expert Opin Drug Metab Toxicol. 2018 Dec;14(12):1303-1313. doi: 10.1080/17425255.2018.1550484. Epub 2018 Nov 23. Expert Opin Drug Metab Toxicol. 2018. PMID: 30451549 Free article. Review.
Hypoxic pulmonary vasoconstriction.
Dumas JP, Bardou M, Goirand F, Dumas M. Dumas JP, et al. Among authors: bardou m. Gen Pharmacol. 1999 Oct;33(4):289-97. doi: 10.1016/s0306-3623(99)00026-9. Gen Pharmacol. 1999. PMID: 10523066 Review.
The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS.
Guerard P, Rakotoniaina Z, Goirand F, Rochette L, Dumas M, Lirussi F, Bardou M. Guerard P, et al. Among authors: bardou m. Naunyn Schmiedebergs Arch Pharmacol. 2006 Sep;373(6):401-14. doi: 10.1007/s00210-006-0082-1. Epub 2006 Aug 1. Naunyn Schmiedebergs Arch Pharmacol. 2006. PMID: 16896805
The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin.
Rakotoniaina Z, Guerard P, Lirussi F, Goirand F, Rochette L, Dumas M, Bardou M. Rakotoniaina Z, et al. Among authors: bardou m. Naunyn Schmiedebergs Arch Pharmacol. 2006 Dec;374(3):195-206. doi: 10.1007/s00210-006-0112-z. Epub 2006 Nov 11. Naunyn Schmiedebergs Arch Pharmacol. 2006. PMID: 17102939
206 results